$-0.73 EPS Expected for BeyondSpring Inc. (BYSI)

May 18, 2018 - By Carrie Sands

Analysts expect BeyondSpring Inc. (NASDAQ:BYSI) to report $-0.73 EPS on May, 28.They anticipate $1.93 EPS change or 72.56 % from last quarter’s $-2.66 EPS. After having $-0.68 EPS previously, BeyondSpring Inc.’s analysts see 7.35 % EPS growth. The stock increased 0.04% or $0.01 during the last trading session, reaching $27.61. About 18,591 shares traded or 26.13% up from the average. BeyondSpring Inc. (NASDAQ:BYSI) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company has market cap of $620.00 million. The firm is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. It currently has negative earnings.

More recent BeyondSpring Inc. (NASDAQ:BYSI) news were published by: Globenewswire.com which released: “BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual Meeting” on April 25, 2018. Also Nasdaq.com published the news titled: “BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the …” on May 17, 2018. Nasdaq.com‘s news article titled: “BeyondSpring to Present at the Deutsche Bank 43rd Annual Health Care Conference” with publication date: May 07, 2018 was also an interesting one.

BeyondSpring Inc. (NASDAQ:BYSI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: